Polyphron, a New York-based company building artificial human biology to transform drug development and treat disease, has announced a $20 million seed financing round. The investment was led by Quiet Capital, with participation from Gradient, Haystack, and Compound. The funding will support the company's efforts to create a physical verification layer for AI-driven biology and accelerate the development of living tissue models.
The Verification Gap in AI-Driven Biology
Artificial intelligence systems are becoming increasingly capable of generating drug candidates, biological hypotheses, and experimental designs. However, the ability to test these ideas in human biology is advancing far more slowly than the ability to generate them. Existing validation methods force researchers to choose between biological relevance and speed, which leaves a significant gap in drug development.
Building a Physical and Simulated Testing System
Polyphron combines AI-driven tissue manufacturing, stem-cell biology, and autonomous experimental infrastructure with tissue world models trained on longitudinal data from living tissues. Together these physical and simulated systems create a closed loop for testing predictions in donor-diverse human tissue. The approach could help predict whether a new drug will cause cardiac or liver toxicity before reaching clinical trials and identify which patients are most likely to respond to treatment.
Manufacturing Human Cardiac and Liver Tissue
The company's first tissue is cardiac and is currently in production in its tissue foundry across multiple donor lines. A broader donor panel is being onboarded to capture the range of human biological variation. Liver tissue will follow later this year, extending the same manufacturing, automation, and measurement stack to drug metabolism and liver toxicity.
Tissue Testing Environments
Polyphron's Tissue Testing Environments integrate physical and simulated human biology into a single system. The Tissue Foundry grows human micro-tissue from stem cells using developmental signals similar to those the body uses during tissue formation. The Tissue World Model is a simulation layer trained on tissue trajectories to predict responses to genetic, chemical, biological, and environmental changes across donors.
Leadership and Strategic Vision
Matthew Osman, co-founder and chief executive officer, believes that artificial intelligence alone will not cure diseases without a reliable verification layer. He explained that generating therapeutic hypotheses is becoming cheaper, but the missing piece is a scalable environment to test predictions against living human biology. Polyphron was co-founded by Osman and Fabio Boniolo, Ph.D., who previously held research roles at Dana-Farber Cancer Institute, the Broad Institute, and Harvard Medical School.
Investor Confidence and Market Potential
Michael Bloch of Quiet Capital said the firm supports founders who are creating infrastructure that expands what is economically possible. He noted that turning tissue into a manufacturable and testable unit at scale could fundamentally change the economics of drug development. Polyphron applies that infrastructure mindset to human biology, according to Bloch.
Expanding the Leadership Team
Earlier this month Vinh Q. Tran joined as an additional co-founder and chief AI scientist after working on post-training and self-improvement research for Gemini at Google DeepMind. George Pilitsis serves as chief operating officer and previously founded and scaled the Datapoints product line at Ginkgo Bioworks. These leadership additions strengthen Polyphron's expertise in AI and scalable biological infrastructure.
Looking Ahead
The long-term objective is to model human response before a clinical trial is run and predict how an intervention will behave across biological diversity. Polyphron also aims to identify who is most likely to respond to a given therapy and search for interventions that move biology toward a desired state. This could significantly reduce the time and cost required to bring new treatments to patients.
Polyphron's $20 million seed round marks a significant step toward building a verification layer for AI-driven biology. By combining automated tissue manufacturing with AI simulation, the company is working to ensure that promising drug candidates can be tested more reliably before entering clinical trials. If successful, this approach could reshape how the pharmaceutical industry evaluates safety, efficacy, and patient-specific responses.